Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 5, 2004, Pages 577-581

  Wang, Hong ^a   Mehta, Jawahar L ^b   Chen, Kui ^b   Zhang, Xingjiang ^b   Li, Dayuan ^b  

^a Renhe Hospital   (China)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Collagen; Endothelial cells; Human urotensin II; MMP; Protein kinases

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; INTERSTITIAL COLLAGENASE; UROTENSIN II;

ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

CELLS, CULTURED; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 1; PHOSPHORYLATION; TIME FACTORS; UMBILICAL VEINS; UP-REGULATION; UROTENSINS;

EID: 7444265142     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200411000-00010     Document Type: Article

References (24)

1. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282-286.
2. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185-2190.
3. Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin II causes fatal circulatory collapse in anaesthesized cynomolgus monkeys in vivo: a " vasoconstrictor" with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol. 2004;286:H830-H836.
4. Tzanidis A, Hannan RD, Thomas WG, et al. Direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93:246.
5. Matsumoto T, Wada A, Tsutamoto T, et al. Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure. Circulation. 2003;107:2555-2558.
6. Orbe J, Rodriguez JA, Arias R, et al. Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis. 2003;167:45-53.
7. Libby P, Schoenbeck U, Mach F, et al. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. Am J Med. 1998;104:145-18S.
8. Shall PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
9. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503-2509.
10. Li D, Mehta JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol. 2000;20:1116-1122.
11. Li D, Liu L, Chen H, et al. LOX-1 Mediates Oxidized LDL-induced the expression and activation of matrix metalloproteinases (MMPs) in human coronary artery endothelial cells. Circulation. 2003;107:612-617.
12. Li D, Singh RM, Liu L, et al. Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovasc Res. 2003;57:238-243.
13. Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol. 2004;43:68-76.
14. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262.
15. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994:23:869-877.
16. Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971-978.
17. Engels W, Reiters PH, Daemen MJ, et al. Transmural changes in mast cell density in rat heart after infarct induction in vivo. J Pathol. 1995;177:423-429.
18. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375-381.
19. Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990-1997.
20. Ng LL, Loke I, O'Brien RJ, et al. Plasma urotensin in human systolic heart failure. Circulation. 2002;106:2877-2880.
21. Nothacker HP, Wang Z, McNeill AM, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol. 1999;1:383-385.
22. Ziltener P, Mueller C, Haenig B, et al. Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. J Recept Signal Transduct Res. 2002;22:155-168.
23. Tamura K, Okazaki M, Tamura M, et al. Urotensin II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 2003;72:1049-1060.
24. Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104:16-18.